Lilly's Cyramza misses liver-cancer target

Share this article:

Eli Lilly's gastric cancer drug Cyramza, previously known as ramucirumab, failed to hit its Phase-III targets among liver-cancer patients using the drug as a second-line treatment. The Wall Street Journal reports that although Cyramza patients had more favorable overall survival rates than placebo patients, the differences were not statistically significant.

The drug failed to hit targets in a breast cancer clinical trial last year, but showed promise in Phase-III tests among non-small cell lung cancer patients when used with docetaxel.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies